China National Uranium Co Ltd

China Uranium, stock code 001280, announced that Chairman Yuan Xu has resigned due to work adjustment. The announcement shows that the board of directors of China Uranium recently received a written resignation report from Yuan Xu, in which he applied to resign from his positions as chairman, director, and convener of the board's strategy and investment committee. His original term was set to end upon the expiration of the second board of directors. After resigning, he will no longer hold any position in the company. According to relevant regulations, Yuan Xu's resignation will not cause the number of board members to fall below the statutory minimum, and his resignation report takes effect from the date it is delivered to the board. It will not have an adverse impact on the company's daily management or production and operations. As of the disclosure date of the announcement, Yuan Xu does not hold any company shares, and there are no commitments that should have been fulfilled but have not been fulfilled. China Uranium stated that during his tenure, Yuan Xu performed his duties diligently and conscientiously, steadily advanced the increase of domestic natural uranium reserves and production, significantly enhanced the ability to control overseas uranium resources, accelerated the development of the comprehensive utilization industry for radioactive associated resources, strengthened top-level design for scientific and technological innovation, and successfully completed the company's initial public offering and listing.

China Animal Husbandry Industry disclosed that it has completed the core process of a cross-central-enterprise industrial acquisition totaling 727 million yuan through public listing. The company used its own and self-raised funds to acquire a 51 percent stake in Hebei Shengxue Dacheng Pharmaceutical from China Nuclear Uranium, as well as a 72.7272 percent stake in Inner Mongolia Shengxue Dacheng Pharmaceutical from China Nuclear Uranium and other transferors. The transaction has passed the concentration review by the State Administration for Market Regulation, the transaction price has been paid in full, and the property rights transaction contract has officially taken effect. After completion, China Animal Husbandry Industry will directly hold 51 percent of Hebei Shengxue Dacheng, and directly and indirectly hold a combined 86.6363 percent of Inner Mongolia Shengxue Dacheng. The two target companies will become controlling subsidiaries and be included in the consolidated financial statements. The two target companies are mainly engaged in the research, development and production of veterinary drug active pharmaceutical ingredients and preparations, which are highly synergistic with China Animal Husbandry Industry's core animal health business. This transaction is a typical practice of specialized coordination and integration among central enterprises.